Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Prostate Screening Fails to Cut Cancer Deaths, Study Says

Sept. 15 (Bloomberg) -- Screening men for prostate cancer saves few lives and comes at the risk of unnecessary treatments, a study found.

The routinely used PSA blood test didn’t reduce the number of cancers or overall deaths, according to a review published today in the British Medical Journal of more than 380,000 men who participated in previous studies.

The study, led by Philipp Dahm of the University of Florida, adds to the evidence that while the PSA blood test detects cancer in its early stages, it doesn’t lead to reduced mortality. The American Cancer Society this year changed its guidelines to reflect the growing uncertainty over testing.

“If we pool together all high-quality studies that exist, rather than picking and choosing evidence, the conclusion is that there is no impact on mortality,” Dahm, an associate professor, said in a telephone interview yesterday.

Dahm’s research used information from six previous studies. While screening raised the chance of being diagnosed with cancer, it didn’t save lives. Finding more tumors early fails to cut deaths in part because prostate cancer grows very slowly, Dahm said.

The study is limited by the fact that it didn’t record the effect on the participant’s quality of life or information on the side effects of screening, Dahm said. The results don’t preclude that a longer follow-up could show some benefit, Dahm said.

Side effects of prostate cancer treatments include incontinence, erectile dysfunction and other complications, according to the National Cancer Institute.

‘Uncertain Benefit’

“In addition to the uncertain benefit on mortality, the human and economic costs associated with PSA-based screening are substantial, primarily as a result of overdiagnosis and overtreatment,” Gerald Andriole, chief of urological surgery at the Washington University School of Medicine in St. Louis, said in an accompanying editorial.

Additional research published today found one test at age 60 helped determine future prostate cancer risk. In a study of 1,167 60-year-olds, Hans Lilja of the Memorial Sloan-Kettering Cancer Center in New York found 90 percent of all mortality in men with the highest levels of PSA, while men with low or average levels had negligible rates of prostate cancer or death by age 85.

In its revised guidelines, the American Cancer Society now says men should only be screened if they have been told of the possibility of misleading test results and side effects of treatments that in some cases may pose more harm than the disease itself.

Annual Test

Prostate cancer was the second-most common malignancy in U.S. men last year with 192,280 new cases, and the second-highest killer with 27,360 deaths, according to the society. About half of men who are 50 or older undergo an annual blood test, even after some studies found routine tests don’t increase survival.

Screening for prostate cancer is done by blood tests that measure levels of PSA, or prostate specific antigen, a protein that can increase because of benign prostate conditions or cancer, according to the National Cancer Institute.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net.

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.